Differentiating FSO and FSP approaches can better align definitions of models for CROs and sponsors.
Dr. Mark Travers
Advertisement
VP, Head of GCTO Regions and Head Quarters Functions at Merck & Co
Articles by Dr. Mark Travers
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Finalizes Guidance on Clinical Trial Design for Psychedelic Drug Development
2
ACT Brief: Organizational Barriers to Programmatic Recruitment, Scaling Selective Safety Data Collection, and Subcutaneous Alzheimer's Treatment
3
ACT Brief: Portfolio-Level Recruitment Strategy, Real-Time Burden Sampling, and Platinum-Free Bladder Cancer Therapy
4
Selective Safety Data Collection and the Case for Simpler Trials: Q&A with Rob DiCicco, TransCelerate Biopharma
5